The prestigious award is in recognition of Cobra’s commercial success in providing services to its global customer base.
In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment.
In the past decade, China's drug market has been expanding in double-digit percentages. This has brought about a huge increase in local drug makers and has lured multinational pharmaceutical companies to develop, manufacture and commercialise their drug products in China.
Research into groundbreaking biologic therapies has significantly shifted the diagnosis and treatment paradigms for many disease categories, particularly in oncology, autoimmune, inflammation and neurology. Discovering and developing an innovative, first-in-class biologic has the potential to offer patients significant benefits as well as add substantially to a developer's bottom-line as these medicines often become the new standard of care. But reaching this goal requires a difficult and seemingly insurmountable journey through the laboratory and the varying phases of clinical research.
The economics of contemporary drug discovery are forcing changes upon the industry at an alarming rate. Even academic and government laboratories are getting into the drug discovery game. Many of the larger pharmaceutical companies at least are turning to academia for their expertise in target identification and target validation.
Continuing research efforts that further refine our understanding of the pathobiological mechanisms in RA has, in turn, led to the development of novel DMARDs acting on these mechanisms.